BRPI0418306A - inibidores da transcriptase reversa não nucleotìdicos - Google Patents
inibidores da transcriptase reversa não nucleotìdicosInfo
- Publication number
- BRPI0418306A BRPI0418306A BRPI0418306-1A BRPI0418306A BRPI0418306A BR PI0418306 A BRPI0418306 A BR PI0418306A BR PI0418306 A BRPI0418306 A BR PI0418306A BR PI0418306 A BRPI0418306 A BR PI0418306A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- orx
- transcriptase inhibitors
- reverse transcriptase
- nrxrx
- Prior art date
Links
- 239000002773 nucleotide Substances 0.000 title 1
- 125000003729 nucleotide group Chemical group 0.000 title 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 title 1
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 abstract 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 abstract 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 229940121357 antivirals Drugs 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
INIBIDORES DE TRANSCRIPTASE RESERVA NãO NUCLEOTìDICOS Compostos de fórmula Z: onde; A é CH ou N; R~ 1~ é um sustituinte para um átomo de carbono no anel contendo A selecionado de -S(=O) ~ p~Ra, onde Ra é -alquilC~ 1~-C~ 4~- ORx, -NRxRx, -NHNRxRx, -NHNHC (=O) ORx, -NRxOH; -C(=O) -Rb, onde Rb é -alquilC~ 1~-C~ 3~-C(=O) ORx -NRxRc, onde Rc é H, alquilC~ 1~-C~ 4~, -NRxRx; -C(=O) Rd, -CN, S (=O) ~ p~Rx onde Rd é Rd é alquilC~ 1~-C~ 4~, -ORx, -NRxRx -alquilC~ 1~-C~ 3~-O-alquilC~ 1~-C~ 3~ C(=O) ORx, -alquilC~ 1~-C~ 3~-COORx; éteres ou ésteres -alquilC~ 1~-C~ 3~-OH ou alquilC~ 1~-C~ 4~ dos mesmos - (O-alquilC1-C3) ~ q~-O-Rx um anel aromático de 5 ou 6 membros tendo de 1-3 heteroátomos p é 1 ou 2; Rx é independentemente selecionado de H, alquilC~ 1~-C~ 4~ ou acetil; ou par de Rx pode junto com o átomo de N adjacente formar um anel; L é -O-, -S(=O)~ r~- ou -CH~ 2~-, onde r é 0, 1 ou 2; R3-R7 são substituintes como definido na especificiação; X é - (CR~ 8~R~ 8~ ) n-D- (CR~ 8~R~ 8~ ) m-; D é uma ligação, -NR~ 9~-, -O-, -S-, -S(=O) - ou -S(=O)~ 2~-; e sais farmaceuticamente aceitáveis e pró- drogas dos mesmos, tendo utilidade como anti-virais para HIV.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0400021A SE0400021D0 (sv) | 2004-01-08 | 2004-01-08 | Non-nucleoside reverse transcriptase inhibitors |
| SE0400585A SE0400585D0 (sv) | 2004-03-09 | 2004-03-09 | NNRTI Antivirals |
| PCT/SE2004/002034 WO2005066131A1 (en) | 2004-01-08 | 2004-12-30 | Non-nucleotide reverse transcriptase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0418306A true BRPI0418306A (pt) | 2007-05-02 |
| BRPI0418306B1 BRPI0418306B1 (pt) | 2018-09-18 |
| BRPI0418306B8 BRPI0418306B8 (pt) | 2021-05-25 |
Family
ID=34752289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0418306A BRPI0418306B8 (pt) | 2004-01-08 | 2004-12-30 | composto n-[(1s,1ar,7br)-4,7-difluoro-1,1a,2,7b-tetraidrociclopropa[c]cromen-1-il]-n-[5-(4-(sulfonamido)fenoxi)-2-piridinil]ureia, composição farmacêutica e uso do dito composto para profilaxia ou tratamento de infecções por hiv-1 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7915295B2 (pt) |
| EP (1) | EP1701942B1 (pt) |
| JP (1) | JP4762917B2 (pt) |
| AT (1) | ATE451357T1 (pt) |
| AU (1) | AU2004312284B2 (pt) |
| BR (1) | BRPI0418306B8 (pt) |
| CA (1) | CA2550187C (pt) |
| DE (1) | DE602004024584D1 (pt) |
| DK (1) | DK1701942T3 (pt) |
| EA (1) | EA009700B1 (pt) |
| ES (1) | ES2337794T3 (pt) |
| IL (1) | IL176740A (pt) |
| NZ (1) | NZ548367A (pt) |
| SG (1) | SG149070A1 (pt) |
| WO (1) | WO2005066131A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1694700A (zh) * | 2002-09-05 | 2005-11-09 | 美迪维尔公司 | 非核苷逆转录酶抑制剂 |
| US7388008B2 (en) | 2004-08-02 | 2008-06-17 | Ambrilia Biopharma Inc. | Lysine based compounds |
| EP1877091B1 (en) * | 2005-04-27 | 2015-03-25 | TaiMed Biologics, Inc. | Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors |
| WO2007062526A1 (en) | 2005-11-30 | 2007-06-07 | Ambrilia Biopharma Inc. | Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation |
| GB0608876D0 (en) * | 2006-05-05 | 2006-06-14 | Medivir Ab | Combination therapy |
| WO2007136572A2 (en) * | 2006-05-15 | 2007-11-29 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
| CA2664118A1 (en) | 2006-09-21 | 2008-07-03 | Ambrilia Biopharma Inc. | Protease inhibitors |
| EP3250552B1 (en) * | 2015-01-30 | 2019-03-27 | Genentech, Inc. | Therapeutic compounds and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ299387B6 (cs) * | 1998-01-16 | 2008-07-09 | Medivir Ab | Antivirové slouceniny |
| WO1999051613A1 (en) | 1998-04-03 | 1999-10-14 | Medivir Ab | Prodrugs of phosphorous-containing pharmaceuticals |
| SE0100733D0 (sv) * | 2001-03-05 | 2001-03-05 | Medivir Ab | Non-nucleoside reverse transcriptase inhibitors |
| SE0102867D0 (sv) * | 2001-08-28 | 2001-08-28 | Medivir Ab | Non-nucleoside reverse transcriptase inhibitors |
| CN1694700A (zh) * | 2002-09-05 | 2005-11-09 | 美迪维尔公司 | 非核苷逆转录酶抑制剂 |
-
2004
- 2004-12-30 EP EP04809207A patent/EP1701942B1/en not_active Expired - Lifetime
- 2004-12-30 WO PCT/SE2004/002034 patent/WO2005066131A1/en not_active Ceased
- 2004-12-30 EA EA200601289A patent/EA009700B1/ru not_active IP Right Cessation
- 2004-12-30 SG SG200809639-8A patent/SG149070A1/en unknown
- 2004-12-30 BR BRPI0418306A patent/BRPI0418306B8/pt not_active IP Right Cessation
- 2004-12-30 AU AU2004312284A patent/AU2004312284B2/en not_active Ceased
- 2004-12-30 DE DE602004024584T patent/DE602004024584D1/de not_active Expired - Lifetime
- 2004-12-30 NZ NZ548367A patent/NZ548367A/en not_active IP Right Cessation
- 2004-12-30 CA CA2550187A patent/CA2550187C/en not_active Expired - Fee Related
- 2004-12-30 US US10/584,933 patent/US7915295B2/en not_active Expired - Fee Related
- 2004-12-30 AT AT04809207T patent/ATE451357T1/de not_active IP Right Cessation
- 2004-12-30 ES ES04809207T patent/ES2337794T3/es not_active Expired - Lifetime
- 2004-12-30 DK DK04809207.6T patent/DK1701942T3/da active
- 2004-12-30 JP JP2006549182A patent/JP4762917B2/ja not_active Expired - Fee Related
-
2006
- 2006-07-06 IL IL176740A patent/IL176740A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EA200601289A1 (ru) | 2006-12-29 |
| DK1701942T3 (da) | 2010-04-06 |
| WO2005066131A1 (en) | 2005-07-21 |
| BRPI0418306B8 (pt) | 2021-05-25 |
| ATE451357T1 (de) | 2009-12-15 |
| DE602004024584D1 (de) | 2010-01-21 |
| JP4762917B2 (ja) | 2011-08-31 |
| AU2004312284A2 (en) | 2005-07-21 |
| EP1701942B1 (en) | 2009-12-09 |
| AU2004312284A1 (en) | 2005-07-21 |
| EA009700B1 (ru) | 2008-02-28 |
| NZ548367A (en) | 2010-06-25 |
| IL176740A (en) | 2011-09-27 |
| SG149070A1 (en) | 2009-01-29 |
| HK1101400A1 (en) | 2007-10-18 |
| US7915295B2 (en) | 2011-03-29 |
| BRPI0418306B1 (pt) | 2018-09-18 |
| US20080070951A1 (en) | 2008-03-20 |
| JP2007519640A (ja) | 2007-07-19 |
| AU2004312284B2 (en) | 2010-08-05 |
| ES2337794T3 (es) | 2010-04-29 |
| EP1701942A1 (en) | 2006-09-20 |
| IL176740A0 (en) | 2006-10-31 |
| CA2550187A1 (en) | 2005-07-21 |
| CA2550187C (en) | 2012-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062109A1 (es) | Derivados sustituidos de espirocetal y uso de los mismos como farmacos terapeuticos para la diabetes. composiciones farmaceuticas. | |
| BRPI0908120A8 (pt) | Compostos que são inibidores de erk, composição faramacêutica e uso | |
| EA200602060A1 (ru) | Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы | |
| SV2010003713A (es) | Pirimidin-5-carboxamidas sustituidas 281 | |
| BRPI0418306A (pt) | inibidores da transcriptase reversa não nucleotìdicos | |
| ECSP099571A (es) | Derivados pirazólicos como inhibidores de la 11-beta-hsd1 | |
| EA201101089A1 (ru) | Производные оксадиазола в качестве агонистов рецептора s1p1 | |
| EA200802209A1 (ru) | Ингибиторы репликации вируса иммунодефицита человека | |
| WO2008087611A3 (en) | Pyrrolidine- and piperidine- bis-amide derivatives | |
| EA201001015A1 (ru) | Карбамоиловые соединения в качестве ингибиторов dgat1 190 | |
| MA30821B1 (fr) | Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes | |
| ECSP099442A (es) | Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona | |
| DE602005016297D1 (de) | Antithrombotische diamide | |
| DK1753723T3 (da) | Substituerede quinolinderivater som mitotiske kinesininhibitorer | |
| EA200970793A1 (ru) | Модуляторы рецепторов, активируемых пролифераторами пероксисом | |
| UY30356A1 (es) | Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos. | |
| WO2008078445A1 (ja) | 重合性化合物及び重合性組成物 | |
| WO2009035020A1 (ja) | 新規ジヒドロナフタレン化合物及びその用途 | |
| BRPI0516112A (pt) | métodos para neuroproteção | |
| EA200970779A1 (ru) | Новое сульфированное соединение сахара и его применение в качестве лекарственного средства | |
| SE0400021D0 (sv) | Non-nucleoside reverse transcriptase inhibitors | |
| MX2007005113A (es) | Nuevos derivados de dicarboxamida. | |
| DK2117552T3 (da) | Anvendelse af kondenserede pyrimidinderivater til behandling af autoimmum- og inflammationssygdomme | |
| AR061741A1 (es) | Nuevos derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| MX2013013256A (es) | Proceso para la preparacion de beta-santalol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/09/2018, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/12/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 17A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2651 DE 26-10-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |